Jill Olydam

Jill Olydam is a Researcher at Erasmus MC, specializing in Dermatology with a focus on atopic dermatitis and Janus kinase (JAK) inhibitors. Her work addresses treatment efficacy, adverse events, and real-world applications of targeted therapies.

• Key collaborations: International Eczema Council, European Academy of Dermatology and Venereology
• Drugs studied: Upadacitinib, Abrocitinib, Tralokinumab, Dupilumab

Research trends: Clinical pharmacology of JAK inhibitors, real-world treatment outcomes, and biomarker development for eczema therapies. She contributes to treatment guidelines and comparative effectiveness research.

Research impact: Publications in high-impact dermatology journals with significant citations and downloads. Her work bridges academic research with practical clinical applications.